MedPath

Alligator Bioscience AB

Alligator Bioscience AB logo
🇸🇪Sweden
Ownership
Public
Established
2000-01-01
Employees
58
Market Cap
-
Website
http://www.alligatorbioscience.com

Clinical Trials

5

Active:2
Completed:3

Trial Phases

1 Phases

Phase 1:5

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 1
5 (100.0%)

Safety and Efficacy of Mitazalimab in Combination with Chemotherapy in Pancreatic Cancer Patients

Phase 1
Active, not recruiting
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
Biological: CD40 agonist mitazalimab in combination with chemotherapy
First Posted Date
2021-05-17
Last Posted Date
2025-01-13
Lead Sponsor
Alligator Bioscience AB
Target Recruit Count
94
Registration Number
NCT04888312
Locations
🇧🇪

Cliniques Universitaires St-Luc, Brussels, Belgium

🇧🇪

Hospital Erasme, Bruxelles, Belgium

🇧🇪

UZA Antwerp, Edegem, Belgium

and more 11 locations

Phase 1 Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of ATOR-1017

Phase 1
Completed
Conditions
Solid Tumor
Neoplasms
First Posted Date
2019-10-30
Last Posted Date
2023-04-24
Lead Sponsor
Alligator Bioscience AB
Target Recruit Count
27
Registration Number
NCT04144842
Locations
🇸🇪

Department of Oncology, Skåne University Hospital, Lund, Sweden

🇸🇪

Fas 1-enheten, Centrum för Kliniska Cancerstudier, Karolinska Universitetssjukhuset, Solna, Sweden

🇸🇪

Department of Oncology, Uppsala University Hospital, Uppsala, Sweden

Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of ATOR-1015

Phase 1
Completed
Conditions
Solid Tumor
Neoplasms
First Posted Date
2018-12-20
Last Posted Date
2022-08-18
Lead Sponsor
Alligator Bioscience AB
Target Recruit Count
33
Registration Number
NCT03782467
Locations
🇩🇰

Phase 1 Unit, Department of Oncology, Rigshospitalet, Copenhagen, Denmark

🇩🇰

Center for Cancer Research, Department of Oncology, Herlev Hospital, Herlev, Denmark

🇸🇪

Kliniska Prövningsenheten, Kliniska Studier Sverige - Forum Söder, Skånes Universitetssjukhus, Lund, Sweden

and more 2 locations

ADC-1013 First-in-Human Study

Phase 1
Completed
Conditions
Neoplasms
Solid Tumors
First Posted Date
2015-03-05
Last Posted Date
2017-03-27
Lead Sponsor
Alligator Bioscience AB
Target Recruit Count
24
Registration Number
NCT02379741
Locations
🇩🇰

Center for Cancer Research, Department of Oncology, Herlev Hospital, Herlev, Denmark

🇸🇪

Kliniska prövningsenheten (KPE), Karolinska University Hospital, Solna, Stockholm, Sweden

🇸🇪

Department of Oncology, Uppsala University Hospital, Uppsala, Sweden

and more 2 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.